Navigation Links
Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic
Date:10/28/2008

to HIV infection.

"These data provide good support for the evaluation of our first ZFN-based ZFP Therapeutic in man," commented Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "It was observed more than ten years ago that individuals carrying the natural CCR5-delta32 mutation were highly resistant to infection by HIV. Consequently, a variety of small molecule and antibody approaches have been tested as potential therapeutics. However, a small molecule or antibody approach requires the constant presence of a sufficiently high concentration of drug to block therapeutically relevant numbers of the CCR5 protein, which is present in thousands of copies on the surface of each T-cell and other tissues in the body. We believe that our ZFN technology provides an approach that circumvents the dosing and potential toxicity issues of a systemic therapy. By specifically modifying only CD4 T-cells, the principal target of HIV pathology, in a one-time exposure of the cells to ZFNs, we can generate a population of R5-tropic HIV-resistant T-cells.

We have shown that these ZFN-modified human cells are made permanently resistant to infection by HIV. Furthermore, the cells selectively survive and expand in an animal after HIV infection, providing a reservoir of healthy and uninfectable immune cells. In a patient, such cells could be available to fight both opportunistic infections characteristic of AIDS and HIV itself. The modified cells exhibited the expected properties of normal CD4 T-cells. These data also demonstrate that ZFN-modified human CD4 T-cells can be produced in the quantities required for the translation of this program into the clinic. We intend to file an investigational new drug (IND) application for this ZFP Therapeutic this year and begin a clinical trial as soon as possible."

Data Reported in the ICAAC/IDSA Presentation

The reported results demonstrate that a one-time exposure to CCR5-specif
'/>"/>

SOURCE Sangamo BioSciences, Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
4. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
5. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
6. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
7. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
8. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
9. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
10. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
11. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015  Axovant Sciences Ltd. (NYSE:  AXON), ... treatment of dementia, today announced that the company ... at 5:45 p.m. EDT following its presentation of ... Conference 2015 (AAIC). The event ... Dr. Lawrence Friedhoff , Chief Development Officer, ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection ... an operator control device that will increase healthcare worker safety and reduce financial ...
(Date:6/30/2015)... ... June 30, 2015 , ... Park Systems , ... scientific research into new classes of Nanoscale Graphene-based materials poised to revolutionize industries ... wonder material of the 21st Century' by the researchers who were awarded the ...
(Date:6/30/2015)... Kent, WA (PRWEB) , ... June 30, 2015 ... ... offers a hydrophilic filter that does not sacrifice selectivity to achieve faster flow ... construction combines extremely fine pores with significant open space to allow easy liquid ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... , , ROCKVILLE, Md. , ... of the PARADIGM trial, a Phase 2 clinical study ... of individuals with suspected central nervous system infection due ... held biotechnology company that develops immunotherapeutics to treat autoimmune ...
... SYDNEY, July 12 /PRNewswire-Asia/ -- Pharmaxis (ASX: ... to voluntarily de-list from the Nasdaq Global,Market ("Nasdaq"). , ... review of the demand from existing and,potential international investors ... on Nasdaq and the volume of Pharmaxis ADS trading,in ...
... ,PROVIDENCE, R.I. [Brown University] Rashid Zia, assistant professor ... winners of the Presidential Early Career Awards for Scientists ... of winners this week. The PECASE award recognizes ... show exceptional potential for leadership at the frontiers of ...
Cached Biology Technology:MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 2MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 3MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus 4Pharmaxis to Voluntarily De-List from Nasdaq 2Brown engineering professor wins prestigious White House award 2
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
(Date:6/16/2015)... QUEBEC CITY , June 16, 2015 /CNW ... announce their partnership centralized around the incorporation of ... mobile point-of-care diagnostic laboratory, the Mo-POD™. This unprecedented ... the BIO International Conference at the ... from June 15 th to ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... The largest genome-wide association study ever conducted on ... has identified 16 new genetic associations related to ... 23andMe, the leading personal genetics company, and the ... examined data for more than 53,000 individuals. The ...
... who give birth vaginally are at increased risk of developing ... a study of Chinese women by researchers at Yale School ... online July 1 in the British Journal of Obstetrics ... labor and delivery made the pelvic floor relax and not ...
... that the key to treating neurodegenerative prion diseases such ... in the ribosome, the protein synthesis machinery of the ... Journal of Biological Chemistry . Prion diseases are ... Examples of prion diseases are scrapie in sheep, mad ...
Cached Biology News:23andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 223andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 3Vaginal delivery ups risk of pelvic organ prolapse 2The ribosome -- a new target for antiprion medicines 2
... (Human Exonic Evidence Based Oligonucleotide) Genome Set ... ) Genome Set contain a collection of ... constitutively expressed exons, allowing interrogation of thousands ... researchers at Stanford University and UCSF, the ...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Biology Products: